| Summary: | 碩士 === 長庚大學 === 醫學生物技術研究所 === 92 === Background: Malignant tumors are at the top leading cause of death in Taiwan in the past decades. Currently, there is no serum marker for detecting oral or nasopharyngeal cancers (ORC or NPC), neither available serum marker with high sensitivity and specificity for breast, lung, and prostate cancers (BC, LC, and PC).
Methods: Affinity purification with magnet beads and MALDI-TOF mass spectrometry analysis were used to screen and identify potential serum tumor markers for BC, LC, PC, ORC, and NPC. Compiled protein profile of each cancer group was compared to normal samples, and the differential spectra were statistically analyzed using bioinformatic softwares.
Results: Since Cu bead can discriminate most differential spectra between normal and tumor group, it was used for protein profiling. Among the five tested malignant diseases except breast cancer, several markers with high sensitivity (>80%) and specificity (>90%) were found. They are 4 LC-specific markers with molecular weight of 2878±5, 3809±5, 4975±5, and 8610±5; 2 PC-specific markers with molecular weight of 1892±5 and 2022±5; 1 ORC-specific marker with molecular weight of 2664±5; and 1 NPC-specific marker with molecular weight of 2020±5. After combination of two NPC-specific markers, the detecting sensitivity was greatly increased (94%0. Finally, two most sensitive and specific markers were identified with a PC and NPC marker (2020 Da) and an ORC marker (2658 Da). They are complement C3 precursor and alpha fibrinogen, respectively.
Conclusion: High-throughput proteomic approach could greatly facilitate the discovery of novel and better serum markers. 4 LC-specific markers, 2 PC-specific markers, 1 ORC-specific marker and 1 NPC-specific marker were found. The high specificity and sensitivity achieved by the use of these tumor-specific markers show great potential for the detection of the malignant diseases.
|
|---|
